Patents by Inventor Anne SADEWASSER

Anne SADEWASSER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotide for reducing the expression of angiotensin-converting enzyme 2 (ACE2) and its use for treating viral infection
    Publication number: 20240067973
    Abstract: The present invention refers to oligonucleotides comprising 10 to 25 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with mRNA of angiotensin-converting enzyme 2 (ACE2) of SEQ ID NO.1 and/or with pre-mRNA of ACE2 of SEQ ID NO.2 resulting in a reduction of the level of ACE2, ACE2 mRNA, ACE2 pre-mRNA or a combination thereof of 30 to 99% compared to an untreated control. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide. The oligonucleotide and the pharmaceutical composition are used in a method of preventing and/or treating a viral disease.
    Type: Application
    Filed: December 31, 2021
    Publication date: February 29, 2024
    Inventors: Frank JASCHINSKI, Anne SADEWASSER, Sven MICHEL, Marta Lucia DE LOS REYES, Richard KLAR, Nan ZHANG, Claus BACHERT, Weiping WEN
  • ANGPTL4 oligonucleotides influencing the regulation of the fatty acid metabolism
    Patent number: 11781139
    Abstract: An ANGPTL4 inhibitor consists of an oligonucleotide has 12 to 22 nucleotides. At least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of human and/or muse ANGPTL4 and inhibits the expression of ANGPTL4. A pharmaceutical composition can include the ANGPTL4 inhibitor and a pharmaceutically acceptable carrier, excipient diluent, or a combination of these.
    Type: Grant
    Filed: February 8, 2022
    Date of Patent: October 10, 2023
    Assignee: Lipigon Pharmaceuticals AB
    Inventors: Frank Jaschinski, Anne Sadewasser, Sven Michel
  • ANGPTL4 OLIGONUCLEOTIDES INFLUENCING THE REGULATION OF THE FATTY ACID METABOLISM
    Publication number: 20220162613
    Abstract: An ANGPTL4 inhibitor consists of an oligonucleotide has 12 to 22 nucleotides. At least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of human and/or muse ANGPTL4 and inhibits the expression of ANGPTL4. A pharmaceutical composition can include the ANGPTL4 inhibitor and a pharmaceutically acceptable carrier, excipient diluent, or a combination of these.
    Type: Application
    Filed: February 8, 2022
    Publication date: May 26, 2022
    Inventors: Frank JASCHINSKI, Anne SADEWASSER, Sven MICHEL
  • ANGPTL4 OLIGONUCLEOTIDES INFLUENCING THE REGULATION OF THE FATTY ACID METABOLISM
    Publication number: 20220010311
    Abstract: An ANGPTL4 inhibitor consisting of an oligonucleotide has 12 to 22 nucleotides. At least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of human and/or mouse ANGPTL4 and inhibits the expression of ANGPTL4. Also disclosed herein is a pharmaceutical composition of the ANGPTL4 inhibitor and a pharmaceutically acceptable carrier, excipient, diluent, or a combination thereof.
    Type: Application
    Filed: November 13, 2019
    Publication date: January 13, 2022
    Inventors: Frank JASCHINSKI, Anne SADEWASSER, Sven MICHEL